BioAtla and Bruce, Call. XXXX Earnings our Thank joining Quarter everyone for thanks for Third us you, to
presentation the and be Also, September website related at updated will available Society and available session. slides press Immunotherapy website from will our of for at presented details are tomorrow for Society on our presentation, website. poster, which on available SITC, conclusion in the at share the in Research we poster the the the which on given company today Melanoma will Cancer, is our what oral release also available be the our to upcoming Additional of are today's
on X treatment vedotin, updates. Now for total of that clinical our evaluated an to ongoing quarter program population. received with response, neck Beginning who prior CAB-RORX-ADC last patient of a our which evaluable responses, XX treatment. XX and difficult-to-treat of cancer observed head monotherapy lines a confirmed We median our out shared patients responses, of in refractory were a X this ozuriftamab activity as we in which of our including assets have underscores patients, complete being ongoing
and drug the strength unmet the need, was We data the designation medical given granted of also candidate that the the Fast FDA. Track shared profound by
presented data demonstrated cut earlier that antitumor we September, activity with In an tolerability. meaningful manageable at ESMO
reported months. X.X Based ORRs cancer a from to range overall head of used cetuximab neck patients methotrexate to docetaxel of care lines and survival on X.X update, of showing this results part duration standard months pretreated patient comparisons responders agents, median the is X at approximately the meaningful and with in with from the which second monotherapy median of population X we have cancer for heavily current studies first ongoing. to of at all prior data median evaluate today's These XX% range and therapy. neck are additional X% of now to of that patients, now these line median view cross-trial a treat X.X As being survival the is overall in response of is confirmed head plus one months, the or
X prior very ozuriftamab to and and second vedotin only these Notably, cancer lines believe clinical patients care emerging therapy. is position We of results head standard in a of CAB-RORX-ADC X plus neck the were line in competitive in the population. for pretreated the median monotherapy has with less as profile our to heavily potential
received proposed from feedback the antibody We or and FDA or patients actionable neck among investigator's monotherapy pivotal recently versus platinum-based vedotin for PD-X disease with progression trial our on therapy. regarding after recurrent head and metastatic choice chemotherapy with ozuriftamab cancer
choice We treatment supportive have of clinical potential with a same to additional accelerated the of possible endpoints prospective that benefit trial design are is that the our FDA the to options by authorization report in pleased support proposed randomized trial follow-up. confirmation and marketing followed investigator
X.X vedotin, ozuriftamab current the a the XW underway. of is supported QXW FDA which randomized schedules, XQ of of At and dose the mg limited dosing per evaluation kg
As in part leading pivotal we overall trial of to design, head now the schedule line III have trial second believe seamless path dose Phase confirming and neck a the cancer. we into the plus
which conditionally recently September, IPI, generated to important ipilimumab and affinity half-life. at was the respect Moving data or for binding in Society preclinical CTLA-X clinical Research now evalstotug, of that Melanoma epitope, similar evalstotug activity. is with active CAP from IPI for and our the to showing We presented antibody to
we to CTLA-X However, this continue tumor-specific of benefits and to safety also receive considerable respect differs patients exposure. absence higher to enabling extended from environment, with binding feature in it normal and demonstrate the believe tissue the will
The will annual study poster be available website also a tomorrow, our unresectable the following melanoma. at conclusion metastatic Phase on first-line presentation. SITC in meeting highlighting our poster that be presenting will or of II We
achieved II reduction. To typically least initial XXX-milligram Five However, has plus either clinical representing dosing. that XXX at dosed approach, CTLA-X a share melanoma evalstotug first-line for using at received per routine received in XX of kilogram PD-X patient X briefly safely or review kilogram milligrams per achieve All ipi level relatively kilogram practice. per embargo kilogram milligram our equivalent; to high ipi and data. with X milligrams equivalent like since considerable the patients X tumor dosing. milligrams milligrams inhibition SITC, patients evalstotug lifted I'd dosing treated the X ipi was is X Phase represents summary our With per
disease several continue experienced AEs additional prior volume standard potential readily early and that X including complete follow-up. severity X adjuvant and X II immunotherapy a responses to partial with tumor no acceptable Grade response to responders, reduction observed treatments have We of their with progression The study relatively without disease Phase the show immune-related treatment low incidence observed our AEs. immune-related and decreasing progression. patients X respond responded courses stable tumor in and continues and with to in date. with have patients suggest tolerability are to profile also to safety now Two Notably, treated
instances higher In to increasing to has permissible an addition, dose is been that now to escalation shown based We on intrapatient led directly have reattainment exposure report tolerability. tolerated disease several doses be decision. control of acceptable evalstotug where investigator's with acceptably
milligrams from patient dose XXX PR to Specifically, melanoma is X,XXX And patient another milligrams eventually higher XXX and dose escalator tumor achieved who XX milligrams decreasing escalated milligrams, a from confirmed XXX was disease. cutaneous milligrams stable to melanoma a cutaneous to at the dose. volume experiencing
XXX from Additionally, disease whose to was milligrams escalated stable dose disease. reattained on metastatic patient with recurrent also melanoma control XXX
the often of is to patients on initiation a has be ongoing arm observing activity, with checkpoint prior believe PD-X FDA to anticipated a unresectable control the antibody in holds the commerce trial of with the data, evalstotug potential to immune where we We or evalstotug our the metastatic which be with recently as optimization guidance evolving Based on made tolerability as doses observations to melanoma ipi III and the to that best-in-class between expand first-line indications possible ipi. used received that can are with year. Consistent and dose potentially higher exposure next to due relationship trials, continue randomized be registrational inhibition and in combined enable that antitumor relative effective. we CTLA-X Phase
vedotin. prior KRAS X mecbotamab had cell whose on in [indiscernible]. known or Now with we encouraging expressing including M-KRAS. mutations, of observed cancer XX we the the responders announced findings experienced X lung evaluable to expressed KRAS non-small Last patients and failure GXXC KRAS variant tumor quarter, CAB-AXL-ADC, mutant patients Among responder our
In variants. patients a activity years, over that addition, for patient a anti-tumor X we with MK-RAS in encouraging response maintained complete now has with been have demonstrating
Importantly, KRAS our survival M-KRAS among overall variants for genotype. the a support tumors treated wild-type expressing compared with to improved patients trend initial finding
XX update, we today's With patients with the with among expressing multiple evaluable to tumors X MK-RAS, continue now across responses confirmed observe variants. antitumor activity MK-RAS different
an median overall is Additionally, overall variants type see still benefit of we mutant continue respectively, X.X to compared XX.X compared which ongoing. a months, with with patients to KRAS months treated to KRAS and survival survival wild among
in Furthermore, signals continues this no a with safety manageable patient safety new identified population. profile
mutant across strategy X are determining AXL of a non-small they available. will cell coupled cell future improved continue seeing high of and path the As patients believe an that forthcoming pivotal are KRAS for We to efficient we different observe cancer. in pan-KRAS supports Details expression. survival update potential lung cancer, trial. with variants lung with non-small be we a correlation on Currently, evaluation K-RAS MK-RAS are a the as overall most our this, we mutant
maximally escalation I/II has been study T well. escalating. dose Phase tolerated Our cell reached, we the yet dose not dose and for actively CAB-EpCAM are is progressing engager The CAB-CDX
antitumor we with activity We T To in commonly release heavy that year. have also cell ongoing a priming X patients with modulate colorectal cytokine is a and with tumor have multiple volume. can volume patients including implemented for patient observed observed disease engagers stable dose date, with with to syndrome occur reduction, tumor
data I the dose next we escalation, our Given continued now of Phase middle the study of around year. readout anticipate
others. this We treat metastatic TCE continue colon, progress a among potential of pancreas, of patients prostate, breast, with with pleased including the of CAB-EpCAM range wide cancers lung, of and to program and tumors, be the our to
we T worldwide cell [indiscernible] engager. preclinical Finally, bispecific agreement a license recently for announced the
the our care while preclinical bispecific now successful CTO referred therapeutics, as asset context out-licensing advancement clinical to XXX. the to of With execution the potential of we TCE lead ensuring this focus to [indiscernible] of on continue programs,
our In active assets. discussions more addition, in collaboration I we or are X of Phase with regarding engaged multiple
in least for one maintaining guidance we Given II near-term the these of continued potential are discussions, a our assets. progress Phase collaboration our for at
increasing shareholder prioritize inflection to value assets while continue through non-dilutive key value-creating our through means, advancing We points.
now review XXXX Rick? financials. With to quarter over the to that, I Rick the third would to turn call like
